Skip to main content
SpringerLink
Log in

Response Evaluation After Radiotherapy

  • Chapter
  • First Online:
Radiotherapy of Liver Cancer

  • 560 Accesses

Abstract

Accurate assessment of the response to radiotherapy is essential to avoid missing the opportunity for early salvage treatment for residual tumors as well as overtreatment in complete responders. The evaluation of radiotherapy response in liver tumors mainly involves the interpretation of imaging studies. Dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) are the most widely used image evaluation tools. Enhancement-based imaging response evaluation criteria, such as the European Association for Study of the Liver (EASL) and the modified Response Evaluation Criteria in Solid Tumors (mRECIST), are more sensitive than the size change-based RECIST and World Health Organization (WHO) criteria. However, early assessment of the tumor response is challenging. Understanding the time frame of imaging changes of the tumor and surrounding irradiated liver parenchyma is essential for accurate assessment. The typical imaging changes of the tumor are gradual reduction in size of the enhancing part and increase of necrosis over time. The focal liver reaction of the irradiated peritumoral liver tissue also changes over time from hyperemia in acute phase to gradual returning to normal enhancement pattern in chronic phase. Thus, accurate response interpretation requires a series of follow-up contrast-enhanced images with careful assessment of consecutive changes. In this chapter, we describe the imaging assessment of radiotherapy response in liver tumors, focusing on hepatocellular carcinoma (HCC).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Haddad MM, Merrell KW, Hallemeier CL, Johnson GB, Mounajjed T, Olivier KR, et al. Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. Abdom Radiol (NY). 2016;41(10):2061–77.

    Article  Google Scholar 

  2. Fu X, Sluka JP, Clendenon SG, Dunn KW, Wang Z, Klaunig JE, et al. Modeling of xenobiotic transport and metabolism in virtual hepatic lobule models. PLoS One. 2018;13(9):e0198060.

    Article  Google Scholar 

  3. Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, Inoue D, et al. Pathology and images of radiation-induced hepatitis: a review article. Jpn J Radiol. 2018;36(4):241–56.

    Article  Google Scholar 

  4. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237–48.

    CAS  PubMed  Google Scholar 

  5. Maturen KE, Feng MU, Wasnik AP, Azar SF, Appelman HD, Francis IR, et al. Imaging effects of radiation therapy in the abdomen and pelvis: evaluating “innocent bystander” tissues. Radiographics. 2013;33(2):599–619.

    Article  Google Scholar 

  6. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(5):1414–24.

    Article  CAS  Google Scholar 

  7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.

    Article  CAS  Google Scholar 

  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.

    Article  CAS  Google Scholar 

  10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

    Article  CAS  Google Scholar 

  11. De Santis M, Alborino S, Tartoni PL, Torricelli P, Casolo A, Romagnoli R. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol. 1997;7(1):10–6.

    Article  Google Scholar 

  12. Tsien C, Cao Y, Chenevert T. Clinical applications for diffusion magnetic resonance imaging in radiotherapy. Semin Radiat Oncol. 2014;24(3):218–26.

    Article  Google Scholar 

  13. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25(26):4104–9.

    Article  Google Scholar 

  14. Yu JI, Park HC, Lim DH, Choi Y, Jung SH, Paik SW, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(4):814–21.

    Article  Google Scholar 

  15. Park HJ, Kim SH, Jang KM, Lim S, Kang TW, Park HC, et al. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease. AJR Am J Roentgenol. 2014;202(1):92–101.

    Article  Google Scholar 

  16. Lo CH, Huang WY, Hsiang CW, Lee MS, Lin CS, Yang JF, et al. Prognostic significance of apparent diffusion coefficient in hepatocellular carcinoma patients treated with stereotactic ablative radiotherapy. Sci Rep. 2019;9(1):14157.

    Article  Google Scholar 

  17. Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol. 2009;48(7):1034–43.

    Article  Google Scholar 

  18. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30–50.

    Article  Google Scholar 

  19. Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys. 2014;88(2):306–11.

    Article  Google Scholar 

  20. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354(5):496–507.

    Article  CAS  Google Scholar 

  21. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94(11):3314–9.

    Article  CAS  Google Scholar 

  22. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32(5):792–7.

    Article  CAS  Google Scholar 

  23. Chung YH, Yu CF, Chiu SC, Chiu H, Hsu ST, Wu CR, et al. Diffusion-weighted MRI and (18)F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation. Eur J Nucl Med Mol Imaging. 2019;46(8):1733–44.

    Article  CAS  Google Scholar 

  24. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51(11):1699–706.

    Article  Google Scholar 

  25. Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, et al. Baseline and post-treatment 18F-fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy. Dig Dis Sci. 2020;65(2):647–57.

    Article  Google Scholar 

  26. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012;118(12):3191–8.

    Article  Google Scholar 

  27. Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. Int J Radiat Oncol Biol Phys. 2019;103(1):169–79.

    Article  Google Scholar 

  28. Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol Biol Phys. 2017;97(5):931–8.

    Article  Google Scholar 

  29. Mastrocostas K, Jang HJ, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, et al. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol (NY). 2019;44(5):1795–807.

    Article  Google Scholar 

  30. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 2005;44(1):13–22.

    Article  Google Scholar 

  31. Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, et al. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One. 2017;12(4):e0176118.

    Article  Google Scholar 

  32. Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, Lee SS, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One. 2014;9(2):e90327.

    Article  Google Scholar 

  33. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147–56.

    Article  CAS  Google Scholar 

  34. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.

    Article  Google Scholar 

  35. Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010;83(996):1063–71.

    Article  CAS  Google Scholar 

  36. Mendiratta-Lala M, Gu E, Owen D, Cuneo KC, Bazzi L, Lawrence TS, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(4):1063–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

    Cheng-Hsiang Lo, Jen-Fu Yang, Po-Chien Shen & Wen-Yen Huang

Authors
  1. Cheng-Hsiang Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jen-Fu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Po-Chien Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Yen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea (Republic of)

    Jinsil Seong

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lo, CH., Yang, JF., Shen, PC., Huang, WY. (2021). Response Evaluation After Radiotherapy. In: Seong, J. (eds) Radiotherapy of Liver Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-16-1815-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-1815-4_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-1814-7

  • Online ISBN: 978-981-16-1815-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation